Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 6, 2005, Pages 233-241

  Kim, Yu C ^a   Shim, Hyun J ^a,b   Lee, Joo H ^a   Kim, Soon H ^b   Kwon, Jong W ^b   Kim, Won B ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

CYP isozymes; DA 8159; DA 8164; Enzyme inducers and inhibitors; Pharmacokinetics; Rats

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2D1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DA 8164; DEXAMETHASONE; DRUG METABOLITE; ISONIAZID; PHENOBARBITAL; QUININE; SILDENAFIL; TROLEANDOMYCIN; UDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME POLYMORPHISM; ERECTILE DYSFUNCTION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT;

ALCOHOL OXIDOREDUCTASES; ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ENZYME INDUCTION; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; MEMBRANE PROTEINS; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 25144480061     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.453     Document Type: Article

References (33)

1. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
2. Shim HJ, Lee EJ, Kim SH, et al. Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. Res Commun Mol Pathol Pharmacol 2000; 108: 275-286.
3. Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. J Pharm Sci 2003; 92: 2185-2195.
4. Choi SJ, Ji HY, Lee H-Y, Kim DS, Kim WB, Lee HS. In vitro metabolism of a novel phosphodiesterase-5 inhibitor DA-8159 in rat liver preparations using liquid chromatography/electrospray mass spectrometry. Biomed Chromatogr 2002; 16: 395-399.
5. Ji HY, Lee HW, Kim HH, et al. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica 2004; 34: 973-982.
6. Kawamura A, Yoshida Y, Kimura N, Oda H, Kakinuma A. Phosphorylation/dephosphorylation steps are crucial for the induction of CYP2B1 and CYP2B2 gene expression by phenobarbital. Biochem Biophys Res Commun 1999; 264: 530-536.
7. Spatzenegger M, Horsmans Y, Verbeeck RK. Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats. Pharmacol Toxicol 2000; 86: 71-77.
8. Halpert JR. Multiplicity of steroid-inducible cytochrome P-450 in rat liver microsomes. Arch Biochem Biophys 1988; 263: 59-68.
9. Correia MA. Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers. In Cytochrome P450. Structure, Mechanism, and Biochemistry, Oritz de Montellano PR (ed), 2nd edn. Plenum Press: New York and London, 1995; 607-630.
10. Hammond AH, Fry JR. Involvement of cytochrome P4502E1 in the toxicity of dichloropropanol to rat hepatocyte cultures. Toxicology 1997; 118: 171-179.
11. Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B, Guzelian PS. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat livers as the glucocorticoid responsive cytochrome P450P. Biochemistry 1985; 24: 2171-2178.
12. Tomkins DM, Otton SV, Joharchi N, et al. Effects of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 1997; 280: 1374-1382.
13. Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, Sellers EM. Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999; 27: 924-930.
14. Sinclair JF, Szakacs JG, Wood SG, et al. Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: Protection by triacetyloleandomycin. Biochem Pharmacol 2000; 59: 445-454.
15. Arlotto MP, Sonderfan AJ, Klaassen CD, Pakinson A. Studies on the pregnenolone-16-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyl transferase. Biochem Pharmacol 1987; 36: 3859-3866.
16. Ross PH, Ciosk BG, Kallweit P, Kauczinski D, Hanstein WG. Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem Pharmacol 1993; 45: 2239-2250.
17. Ryan DE, Ramanathan L, Iida S, Thomas PE. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 1985; 260: 6385-6393.
18. Choi YM, Kim SH, Lee MG. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J Pharm Sci 1991; 80: 638-642.
19. Williams JF, Lowitt S, Szentivanyi A. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-fife and urinary excretion profile of theophylline and its metabolites in rats. Biochem Pharmacol 1979; 28: 2935-2940.
20. Shim HJ, Lee EJ, Jung YH, et al. Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 2002; 30: 527-533.
21. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
22. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker: New York, 1982.
23. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
24. Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 1980; 69: 90-91.
25. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
26. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
27. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
28. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
29. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45: 382-392.
30. Jones EJ, Riddick DS. Regulation of constitutive rat hepatic cytochrome P450 by 3-methylcholanthrene. Xenobiotica 1996; 26: 995-1012.
31. Lewis DFV. P450 substrate specificity and metabolism. In Cytochromes P450. Structure, Function and Mechanism. Taylor & Francis: Bristol, 1996; 122.
32. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004; 20: 195-217.
33. Tsukamoto S, Tomise K, Miyakawa K, et al. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper. Bioorg Med Chem 2002; 10: 2981-2985.